As the usual flurry of deals coincides with the J.P. Morgan Healthcare Conference, AbbVie signed an mRNA pact with Anima and a cancer research tie-up with Immunome.

Amgen has signed two big early-stage deals in a matter of days, signalling that antibody-drug conjugates are a priority target in oncology for the firm.

PDS is getting rights to Merck's M9241, a tumor-targeting interleukin-12 fusion compound which is a key component, together with its own investigational HPV16-targeted immunotherapy, in a triple combination being studied to treat advanced HPV-positive cancers.

Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.